Research Article

Synthesis, Cytotoxic Activity, and DNA Binding Properties of Copper (II) Complexes with Hesperetin, Naringenin, and Apigenin

Mingxiong Tan,1,2 Jinchan Zhu,1 Yingming Pan,1 Zhenfeng Chen,1 Hong Liang,1 Huagang Liu,3 and Hengshan Wang1

1 The Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry & Chemical Engineering, Guangxi Normal University, Guilin 541004, China
2 Department of Chemistry and Biology, Yulin Normal College, Yulin 537000, China
3 Department of Pharmacology, Guangxi Medical University, Nanning 530021, China

Correspondence should be addressed to Hengshan Wang, wang_hengshan@yahoo.com.cn

Received 28 May 2009; Revised 28 July 2009; Accepted 4 August 2009

Recommended by Lorenzo Pellerito

Complexes of copper (II) with hesperetin, naringenin, and apigenin of general composition \([\text{CuL}_2(\text{H}_2\text{O})_2] \cdot n\text{H}_2\text{O} (1–3)\) have been synthesized and characterized by elemental analysis, UV-Vis, FT-IR, ESI-MS, and TG-DTG thermal analysis. The free ligands and the metal complexes have been tested in vitro against human cancer cell lines hepatocellular carcinoma (HepG-2), gastric carcinomas (SGC-7901), and cervical carcinoma (HeLa). Complexes 1 and 3 were found to exhibit growth inhibition of SGC-7901 and HepG2 cell lines with respect to the free ligands; the inhibitory rate of complex 1 is 43.2% and 43.8%, while complex 3 is 46% and 36%, respectively. The interactions of complex 1 and its ligand Hsp with calf thymus DNA were investigated by UV-Vis, fluorescence, and CD spectra. Both complex 1 and Hsp were found to bind DNA in intercalation modes, and the binding affinity of complex 1 was stronger than that of free ligand.

Copyright © 2009 Mingxiong Tan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

The success of cisplatin and its derivatives as anticancer agents has stimulated the development of metal-based compounds [1–4]. Recently, interests possessed in copper(II) complexes are increasing due to their possible medical uses as antitumor agents. And, new bioactive ligands, involving natural product ligands [5–7], have been applied for the design of Cu-coordination novel drugs; for that, naturally occurring compounds have served as a major source of drugs for centuries [8–10].

Flavonoids are phenolic compounds widely distributed in plants, which display a variety of biological activities, such as antioxidant, anti-inflammatory, blood lipid-lowering, and anticarcinogenic activities [11–13]. Many flavonoids are natural chelators and, flavonoid metal complexes have showed significantly higher cytotoxic activity than those of the parent flavonoids, such as quercetin, morin, and chrysin and so forth [14–16]. Besides, it is demonstrated that the coordination of copper(II) ion with bioactive ligands can actually improve the pharmaceutical activity of the drugs themselves and reduce their toxicity effects [17–19].

Hesperetin (5, 7, 3′-tri hydroxy-4′-methoxy-flavanone, Hsp, Scheme 1), naringenin (4′, 5, 7-tri hydroxyflavanone, Nrg, Scheme 1) and Apigenin (4′, 5, 7-tri hydroxyflavone, Apg, Scheme 1), are biologically active flavonoids, commonly found in fruits and vegetables [20]. They have been reported to exhibit antitumor effects against breast cancer and hepatoma HepG2 cell lines [21, 22]. In addition, some metal complexes of Hsp and Nrg have been found to exhibit antioxidant and anticancer activities [23, 24]. Nrg schiff-base La(III) complex against the A-549 cell line was more potent than cisplatin at most experimental concentrations [25, 26]. Also, Cu(II) complex of Nrg schiff-base possessed potent antioxidant activity and better than standard antioxidants like vitamin C and mannitol [27].
The aim of this study is to prepare new copper(II)-based antitumor compounds and investigate the synergistic effects upon flavonoids coordination with Cu(II) ion. In this paper, three copper(II) complexes with Hsp, Nrg, and Apg have been synthesized and characterized by elemental analysis, UV-Vis, FT-IR, ESI-MS, and TG-DTG thermal analysis, and their cytotoxic activities were estimated against HepG-2, SGC-7901, and HeLa cell lines in vitro. The binding properties with calf thymus DNA of Hsp and its Cu(II) complex, which have good activities against the tested cell lines, were investigated through UV-Vis, fluorescence, and circular dichroism (CD) spectroscopy.

2. Experimental

2.1. Instrumentation and Materials. Hesperetin, naringenin, and apigenin were purchased from Shaanxi Huike Botanical Development Co., Ltd., and the products (compounds purity > 98%) were identified by spectral methods. The solvents and metallic salts used were analytical grade. All the materials were used as received without further purification unless noted specifically. Tris-HCl-NaCl buffer solution (5 mM Tris, 50 mM NaCl, pH was digitzed to 7.35 by titration with hydrochloric acid) and double distilled water were employed for

2.2. Synthesis of Complexes. Synthesis of \([Cu(Hsp)_2(H_2O)_2] \cdot H_2O\) (1): An ethanol solution (10 mL) of Hsp (0.0604 g, 0.2 mmol) was added to a aqueous solution (15 mL) of CuCl_2 · 2H_2O (0.0204 g, 0.12 mmol) and was adjusted pH to 7-8 with ammonia solution. The mixture was refluxed with stirring for 12 hours, and brown precipitate formed during reflux and then allowed to cool to room temperature and filtered. The solid was washed with water and ethanol, and then air-dried for 2 days.

Synthesis of \([Cu(Nrg)_2(H_2O)_2] \cdot H_2O\) (2): this green compound was synthesized by the same method as that employed for 1. Calc. for \([Cu(Nrg)_2(H_2O)_2] \cdot H_2O\): C, 53.37; H, 4.48. Found: C, 53.68; H, 4.51%. IR (KBr): 3423, 1614, 1564, 1356, 1166 cm⁻¹. ESI-MS: m/z 703.

Synthesis of \([Cu(Apg)_2(H_2O)_2] \cdot H_2O\) (3): this yellow-green compound was synthesized by the same method as that employed for 1. Calc. for \([Cu(Apg)_2(H_2O)_2] \cdot H_2O\): C, 56.47; H, 3.48. Found: C, 56.81; H, 3.76%. IR (KBr): 3413, 1626, 1597, 1356, 1176 cm⁻¹. ESI-MS: m/z 638.

2.3. Cytotoxic Activity Assay In Vitro. Cell lines: human cancer cell lines hepatocellular carcinoma (HepG-2), gastric carcinomas (SGC-7901), and cervical carcinoma (HeLa) were obtained from Shanghai Cell Bank in Chinese Academy of Sciences. Cell lines (Gibco, Scotland, UK) were grown in Dulbecco’s modified Eagles medium (DMEN) at 37°C in a humidified atmosphere of 5% CO₂/95% air. Cytotoxicity evaluation: assays of cytoxicity were conducted in 96-well, flat-bottomed microtitre plates. The supplemented culture medium with cell lines was added to the wells. Compounds were dissolved in the culture medium with 1% DMSO to various concentrations, and the solutions were subsequently added to a set of wells. Control wells contained supplemented media with 1% DMSO. The microtiter plates were incubated at 37°C in a humidified atmosphere of 5% CO₂/95% air for
the cultures were incubated further for 4 hours at 37°C in a humidified atmosphere of 5% CO2/95% air. After removal of the supernatant, DMSO (150 μL) was added to dissolve the formazan crystals. The absorbance was read by enzyme labelling instrument with 570/630 nm double wavelength measurement.

2.4. DNA Binding. The UV-Vis absorption titrations, fluorescence emission spectra, and CD absorption spectra studies were performed at room temperature. Hsp and its Cu(II) complex were all dissolved in a small amount of DMSO due to their poor solubility, then diluted to a concentration of 2.0 × 10^{-5} mol/L with Tris-HCl-NaCl buffer solution (5 mM Tris, 50 mM NaCl, pH = 7.35). Absorption titrations were performed by using a fixed compound concentration (2.0 × 10^{-5} mol/L); ct-DNA stock solution (1.0 × 10^{-4} mol/L) was added 30 μL each time and gradually increased up to a sufficient concentration for studying. While measuring the absorption spectra, the solutions were allowed to incubate for 10 minutes before the absorption spectra were recorded, and an equal amount of ct-DNA was added to both the compound solution for the reference solution to eliminate the absorbance of ct-DNA itself. Fluorescence Emission spectra of compounds were performed by using a fixed compound concentration (2.0 × 10^{-5} mol/L) and an increasing amount of DNA (1.0 × 10^{-4} mol/L). Samples were observed between 200 and 800 nm. The CD absorption spectra of ct-DNA (1.0 × 10^{-4} mol/L) were recorded in the absence and presence of compounds (2.0 × 10^{-5} mol/L). The sample solutions were mixed and allowed to equilibrate at room temperature for 60 minutes before measurements. Each sample solution was scanned in the range 200–400 nm UV-Vis region with a screening rate of 100 nm/min at room temperature.

3. Results and Discussion

3.1. Synthesis of the Complexes. The Cu(II) complexes were synthesized by aqueous solution of CuCl2·2H2O and the ethanol aqueous solution of Hsp, Nrg or Apg in 1 : 2 molar ratio (metal salt/ligands). Ligands were deprotonated by adding ammonia solution. The structures of copper(II) complexes were characterized by elemental analysis, UV-Vis, FT-IR, UV-Vis, TG-DTG, and ESI-MS measurements.

The elemental data analysis of the copper(II) complexes agreed with the theoretical values within the limit of experimental error. The ESI-MS of complexes were investigated in H2O-DMSO (1 : 1) solution, the characteristic peaks at m/z 703 and 642 corresponding to [M+H2O]+ of complexes 1 and 2, and that of peak at m/z 638 assigning to [M +H]+ of complex 3.

UV-Vis spectrum of free ligands and their Cu complexes suggested that 4-keto and 5-hydroxy region of the flavonoids may be considered as the possible chelating sites. For example, free Apg exhibits an UV-Vis absorption maximum in DMSO solution at 206–250 nm, corresponding to the A ring portion, and a weak band at 268–316 nm, corresponding to the B ring portion. Upon binding with the Cu(II) ion, forming complex 3, the maximum absorption band is shifted to 235–286 nm and the weak band shifted to 290–340 nm with respect to the free flavonoid, suggesting an interaction of the Cu(II) ion with the condensed ring of the flavonane in positions 4 and 5. These results are in agreement with the results of others, [28–31] which indicate that this band shift is caused by the binding of the metal ion in this position.

FT-IR spectrum data in KBr of free ligands and their Cu complexes were compared in Table 1. The absorption around 3200 cm⁻¹ due to phenolic hydroxyl in the free ligands shows significantly spectral change in all the Cu complexes, indicating the chelate formation through hydroxyl group. The Cu complexes show a medium broad band around 3400 cm⁻¹ indicating coordinated water, later confirmed by TG-DTG thermal analysis. The intense absorption bands due to ν(C=O) of free ligands at 1630–1650 cm⁻¹ has also shifted to lower frequencies at 1623–1626 cm⁻¹ in the Cu complexes. Thus it suggests that flavonoids are coordinated with Cu(II) through oxygen atoms of –OH and C=O groups [31]. This contention is further confirmed by the presence of ν(M–O) bands at about 600 cm⁻¹ in the far IR frequency region.

The TG-DTG curves and thermal data for the dehydration and decomposition of the complexes are given in Table 1 and Figure 1. The results showed that the thermal decomposition of complex 1 displayed three stages from 30°C to 600°C. The first stage of decomposition from 30°C to 100°C was connected with the dehydration processes. The mass loss value of 2.09% was involved in the loss for two water molecules in the outer coordination sphere, which

| Compound | ν(C=O) | ν(C=C) | ν(C–OH) | ν(O–H) | ν(M–O) |
|----------|--------|--------|---------|--------|--------|
| Apg      | 1651   | 1608   | 1354    | 3291   | —      |
| Apg·Cu   | 1626   | 1597   | 1356    | 3413   | 607    |
| Hsp      | 1636   | 1612   | 1360    | 3132   | —      |
| Hsp·Cu   | 1614   | 1564   | 1375    | 3423   | 598    |
| Nrg      | 1629   | 1603   | 1388    | 3290   | —      |
| Nrg·Cu   | 1613   | 1566   | 1374    | 3401   | 595    |

Table 2: Thermal analytical data for complexes.

| Compound | Dehydration temperature (°C) | Decomposition temperature (°C) |
|----------|-----------------------------|-------------------------------|
| Hsp·Cu   | T1: 100, T2: 250, Weight loss (%): 7.2, T3: 347, T4: 540, Total weight loss (%): 55.9 |
| Nrg·Cu   | T1: 94, T2: 117, Weight loss (%): 7.9, T3: 248, T4: 440, Total weight loss (%): 76.5 |
| Apg·Cu   | T1: 247, T2: 5.2, Weight loss (%): 420, T3: 580, Total weight loss (%): 55.9 |

T1–T2: temperature range corresponding to complex dehydration; T3–T4: temperature range corresponding to complex decomposition.
was in close agreement with the calculated mass loss value of 2.6%. The next dehydration processes appeared in the temperature ranges from 250°C to 300°C. In fact, it was very difficult to distinguish between the dehydration steps for inner and outer spheres from the graphic data. However, the total observed mass loss value of 5.2% was in close agreement with the calculated mass loss value of 5.13% for the two coordinated water molecules. The last mass loss stages were considered as the case of the decomposition of the ring breaking of the ligand and the formation of metal oxide. Complex 2 exhibits a sharp weight loss at temperature of about 253°C–440°C, which corresponds to the degradation of the ligand molecules and the formation of metal oxides. The dehydration process occurs at temperature range of 30°C–94°C and 124°C–253°C, corresponding to the outer sphere and coordinated water molecules. The thermal decomposition process of complex 3 is basically the same as that of complex 1. The dehydration process occurs in only one mass-loss step up to 247°C with 5.2%, which is in close agreement with the calculated mass loss value of 5.5% for the two coordinated water molecules in inner spheres.

Based on these results, the possible structures of the complexes were suggested. As shown in Scheme 2, the copper(II) complexes have the general formula \([\text{Cu}(\text{L})_2(\text{H}_2\text{O})_2] \cdot n\text{H}_2\text{O}\), where \(\text{L}\) is the ligands, and \(n = 0\) for Apg, and \(n = 1\) for Hsp or Nrg. The complexes are air stable for extended periods and soluble in DMF, dimethyl sulphoxide (DMSO), slightly soluble in \(\text{Me}_2\text{CO}\), and \(\text{CH}_3\text{OH}\), but scarcely soluble in water.

3.2. Cytotoxic Activity Assay In Vitro. Cytotoxicities in vitro of Hsp, Nrg, and Apg and their copper(II) complexes have been estimated by MTT assay [32] against three typical human tumour cell lines involving HepG-2, SGC-7901 and HeLa. As shown in Figure 2, it is remarkable that complexes 1 and 3 exhibited cytotoxicity higher than that of complex 2 against the selected cell lines. Against the SGC-7901 tumour cell line, the activity of complex 1 is 43.2%, while 3 is 46%, fifteen times stronger than that of Apg, and against HePG2, the activity of complex 1 is 43.8%, while complex 3 is 36%, ten times stronger than that of Apg. However, complex 2 showed relatively significant inhibitory rate only against HepG2 cell line than that of Nrg.

Nrg and Apg are structurally similar with the same A and B rings, and Apg is a planar molecule in its rings A and C. The ligand Apg was found to show lower activities against the tested cell lines than the analogous ligand Nrg. However, the Cu(II) complex of Apg exhibited higher activity than the Cu(II) complex of Nrg, presumably the flavone planar structure of Apg is important for retaining its original planarity in the Cu(II) complex and plays an important role in the enhanced antitumour activity of the complex [33]. It is noteworthy that, Hsp and Nrg share similar structures but have different hydroxyl (OH) substitutions in ring B. In contrast to the inhibitory activity of the Cu(II) complexes of Nrg and Hsp, the high activity of Cu(II) complex with Hsp may be related to the different hydroxyl (OH) substitutions in ring C and the synergistic action of copper(II) ion with ligands [34–36].

3.3. DNA Binding Studies of 1 and Hsp. DNA is the primary pharmacological target of many antitumor compounds. Conformational changes of DNA directly affect genetic expression, which is closely related to carcinogenesis and anticarcinogenesis. Similarly, interactions between small molecules and DNA rank among the primary action mechanisms of antitumour activity. DNA replication in tumour cells will be blocked by the intercalation of small
molecule between the base pairs of DNA [37, 38]. Generally, active compounds are required to possess approximately planar structure, with a medium-sized planar area and some hydrophobic character. In order to investigate the binding properties with DNA of Hsp and its copper(II) complexes, which have significant effects against the tested cell lines, a series of spectroscopic studies including UV-Vis, fluorescence, and CD spectra were carried out.

It is well documented that complexes copper(II) are capable of interaction with nucleic acids [39–41], and intercalative $\pi \pm \pi$ stacking of the aromatic rings of the metal complexes with the DNA bases affects the transition dipoles of the molecules and usually leads to a reduction in its absorbance [42]. The absorption titrations were carried out to determine the DNA binding of Hsp and its copper(II) complex in tris(hydroxymethyl)aminomethane (Tris) buffer.

The UV-Vis absorption spectra of Hsp and complex 1 in the absence and presence of calf thymus DNA are shown in Figure 3. The results indicated that the absorption spectrum of Hsp was similar to that of complex 1 with an intense absorption band around 322 nm. After the addition of ct-DNA, the absorption bands of Hsp and complex 1 at 322 nm both exhibited obvious hypochromism about 30.3% for Hsp, 39.4% for complex 1, although there was no obvious red shift.

In order to investigate the interaction pattern of Hsp and complex 1 with ct-DNA, fluorescence emission titration analyses were undertaken. The fluorescence emission spectra of Hsp and complex 1 in the absence and presence of calf thymus DNA are shown in Figure 4. Hsp showed a weak emission band around 284 nm, and complex 1 exhibited a strong emission band around 361 nm. With the addition of ct-DNA, the emission intensity of Hsp caused decrease, whereas that of complex 1 displayed enhancement. The emission intensity decrease of Hsp in the presence of DNA may be caused by the fact that Hsp being a small hydrophobic molecule can be adsorbed by hydrophobic group on the surface of DNA. Such a characteristic change is often observed in DNA interactions [14]. The emission intensity increase of complex 1 on addition of ct-DNA is ascribed to a decrease of the collisional frequency of the solvent molecules with the complex which caused by the planar aromatic group of the complex stacks between adjacent base pairs of ct-DNA [43]. Moreover, the emission intensity of Hsp decreased significantly reaching saturation with an decreasing ratio of 7.26 at the [DNA]/[Hsp] ratio of 8 : 1, whereas that of complex 1 enhanced reaching saturation with an incremental ratio of 1.94 at the [DNA]/[Hsp] ratio of 5 : 1. These variations may be caused by the fact that the interaction degree was related to the planar area and hydrophobic character, suggesting the binding affinity of complex 1 is stronger than that of free ligand.

Circular dichroism (CD) is a useful technique to assess whether nucleic acids undergo conformational changes as a result of complex formation or changes in the environment [44]. The DNA helix has a right-hand chiral structure,
maintaining the B conformation in solution. The CD absorption spectrum is very sensitive to conformational changes in DNA; generally, in noncovalent binding states, electrostatic and groove bindings show no significant CD spectral perturbation, because these two binding modes do not influence the secondary structure of DNA. The observed intensity change can be attributed to an intercalation mode when small planar molecules interact with DNA.

As shown in Figure 5, the CD spectra of ct-DNA show a positive band at 275 nm and a negative band at 245 nm, due to base stacking and right-hand helicity, respectively, consistent with the characteristic B conformation of DNA [45, 46]. With addition of the compounds, the intensities of the negative and positive bands decrease, but no red shift is observed. These alterations in the CD spectrum of DNA indicate strong conformational changes by Hsp and complex 1. Also, Hsp and complex 1 bind DNA mainly by intercalation mode.

Based on the UV-Vis spectral, fluorescence and CD measurements revealed that, with the addition of increasing ct-DNA, complexes exhibited obviously hypochromism, fluorescence emission intensity enhancement, and CD spectrum change, which are important evidences of complex interacting with the DNA by intercalation. In summary, Hsp and complex 1 bind DNA mainly by intercalation mode, and the binding affinity of complex 1 is stronger than that of free ligand.

In addition, interactions of complexes 2 and 3 and their ligands with calf thymus DNA were also investigated under the same experiment condition. Similar results were
obtained, and no obvious differences in the DNA binding mode were founded.

4. Conclusion

Three flavonoids copper(II) complexes were synthesized, and their cytotoxic activities were estimated against HepG-2, SGC-7901 and HeLa cell lines in vitro. The results showed that complexes 1 and 3 showed higher inhibitory rate than their free ligands against SGC-7901 and HepG2 cell lines; the inhibitory rate of complex 1 was 43.2% and 43.8%, while complex 3 was 46% and 36%, respectively. In comparison with complex 2, complexes 1 and 3 exhibited higher cytotoxicity towards selected cell lines, and complex 2 showed relatively significant inhibitory rate only against HepG2 cell lines than that of Nrg. The difference in inhibition rates between the Cu(II) complexes of Apg and Nrg was presumably due to the flavone planar structure of Apg. In contrast to the inhibitory activity of the Cu(II) complexes with Nrg and Hsp, the high activity of Cu(II) complex with Hsp may be related to the different hydroxyl (OH) substitutions in ring B. The binding properties with calf thymus DNA revealed that Hsp and its Cu(II) complex bind DNA mainly by intercalation mode. It confirmed that DNA is an important target in cellular systems for these metal-based compounds derived from flavonoids. The most important contribution of this research is that the synergistic enhancement effects of flavonoids with copper(II) ion may be benefit to further development as promising potential metal-based anticancer drug.

Acknowledgments

This study was supported by 973 project (2007CB516805), Key Technology R&D program (no. 2006BAI06A18-14), the Natural Science Foundation of Guangxi Province (no. 05112001-3B2, 0832096, and 0832024), and the Project of the Key Laboratory of Medicinal Chemical Resources and Molecular Engineering, Guangxi Normal University, China (0630006-5D09), as well as Guangxi’s Medicine Talented Persons Small Highland Foundation (0808).

References

[1] K. Tanaka, A. Tengeji, T. Kato, N. Toyama, M. Shiro, and M. Shionoya, “Efficient incorporation of a copper hydroxypyridine base pair in DNA,” Journal of the American Chemical Society, vol. 124, no. 42, pp. 12494–12498, 2002.
[2] A. P. Kozikowski, W. Tuckmantel, and G. Powis, “Synthesis and biological activity of D-3-deoxy-3-fluorophosphatidylinositol. A new direction in the design of non-DNA targeted anticancer agents,” Angewandte Chemie, vol. 31, no. 10, pp. 1379–1381, 1992.
[3] L.-J. Ming, “Structure and function of “metalloantibiotics”,” Medicinal Research Reviews, vol. 23, no. 6, pp. 697–762, 2003.
[4] D.-L. Ma and C.-M. Che, “A bifunctional platinum(II) complex capable of intercalation and hydrogen-bonding interactions with DNA: binding studies and cytotoxicity,” Chemistry, vol. 9, no. 24, pp. 6133–6144, 2003.
[5] K. Toshima, H. Ouchi, Y. Okazaki, et al., “Artificial anthraquinone-carbohydrate hybrids: design, synthesis, DNA binding, and cytotoxicity,” Angewandte Chemie, vol. 36, no. 24, pp. 2748–2752, 1997.
[6] W. Dürckheimer, “Tetracyclines: chemistry, biochemistry, and structure-activity relations,” Angewandte Chemie, vol. 14, no. 11, pp. 721–734, 1975.
[7] R. F. Anderson, S. S. Shinde, M. P. Hay, and W. A. Denny, “Potentiation of the cytotoxicity of the anticancer agent tirapazamine by benzotriazine N-oxides: the role of redox equilibria,” Journal of the American Chemical Society, vol. 128, no. 1, pp. 245–249, 2006.
[8] P. M. Takahara, C. Frederick, and S. J. Lippard, “Crystal structure of the anticancer drug cisplatin bound to duplex DNA,” Journal of the American Chemical Society, vol. 118, no. 49, pp. 12309–12321, 1996.
[9] D. Steinborn, H. Junicke, and C. Bruhn, “Carbohydrates coordinated to platinum(IV) through hydroxyl groups: a new class of platinum complexes with bioactive ligands,” Angewandte Chemie International Edition, vol. 36, no. 23, pp. 2686–2688, 1997.
[10] I. Kostova, G. Momkova, T. Tzanova, and M. Karaivanova, “Synthesis, characterization, and cytotoxic activity of new lanthanum(III) complexes of bis-coumarins,” Bioinorganic Chemistry and Applications, vol. 2006, p. 25651, 2006.

[11] A. Garg, S. Garg, L. J. D. Zaneveld, and A. K. Singla, “Chemistry and pharmacology of the Citrus bioflavonoid hesperidin,” Phytotherapy Research, vol. 15, no. 8, pp. 655–669, 2001.

[12] D. Susanti, H. M. Sirat, F. Ahmad, R. M. Ali, N. Aimi, and A. Garg, S. Garg, L. J. D. Zaneveld, and A. K. Singla, I. Kostova, G. Momekov, T. Tzanova, and M. Karaivanova, “Antioxidant and chelating activity of naringenin-2-hydroxy benzoyl hydrazone ligand,” European Journal of Medicinal Chemistry, vol. 43, no. 8, pp. 1688–1695, 2008.

[13] S. Kanno, A. Tomizawa, T. Ohtake, K. Koiwai, M. Ujibe, and D. Susanti, H. M. Sirat, F. Ahmad, R. M. Ali, N. Aimi, and A. Garg, S. Garg, L. J. D. Zaneveld, and A. K. Singla, “Synthesis, characterization, antioxidant activity and DNA-binding studies of two rare earth(III) complexes with naringenin-2-hydroxy benzoyl hydrazone ligand,” European Journal of Medicinal Chemistry, vol. 43, no. 8, pp. 1688–1695, 2008.

[14] Y. M. Song, J. W. Kang, Z. H. Wang, X. Q. Lua, J. Z. Gao, and L. F. Wang, “Study on the interactions between CuL and Morin with DNA,” Journal of Inorganic Biochemistry, vol. 91, no. 3, pp. 470–474, 2002.

[15] Y.-B. Zeng, N. Yang, W.-S. Liu, and N. Tang, “Synthesis, characterization and DNA-binding properties of La(III) complex of chrysins,” Journal of Inorganic Biochemistry, vol. 97, no. 3, pp. 258–264, 2003.

[16] J. Zhou, L.-F. Wang, J.-Y. Wang, and N. Tang, “Synthesis, characterization, antioxidative and antitumor activities of solid quercetin rare earth(III) complexes,” Journal of Inorganic Biochemistry, vol. 83, no. 1, pp. 41–48, 2001.

[17] S. Zhang, C. Tu, X. Wang, et al., “Novel cytotoxic copper(II) complexes of 8-aminoquinoline derivatives: crystal structure and different reactivity towards glutathione,” European Journal of Inorganic Chemistry, vol. 2004, no. 20, pp. 4028–4035, 2004.

[18] M. Baldini, M. B. Ferrari, F. Bisceglie, G. Pelosi, S. Pinelli, and P. Tarasconi, “Cu(II) complexes with heterocyclic substituted thiosemicarbazones: the case of 5-formyluracil. Synthesis, characterization and DNA-binding properties of La(III) complex,” Journal of Inorganic Biochemistry, vol. 42, no. 6, pp. 2049–2055, 2003.

[19] X. Sheng, X. M. Lu, Y. T. Chen, et al., “Synthesis, DNA-binding, cleavage, and cytotoxic activity of new 1,7-Dioxo-4,10-diazacyclocdecane artificial receptors containing bis-guanidinioethy or diaminoethy double side arms,” Chemistry, vol. 13, no. 34, pp. 9703–9712, 2007.

[20] E. Tripoli, M. L. Guardia, S. Giammanco, D. D. Majo, and M. Giammanco, “Citrus flavonoids: molecular structure, biological activity and nutritional properties: a review,” Food Chemistry, vol. 104, no. 2, pp. 466–479, 2007.

[21] L. G. Korkina and I. B. Afanas'ev, “Antioxidant and chelating properties of flavonoids,” Advances in pharmacology, vol. 38, pp. 151–163, 1997.

[22] R. M. S. Pereira, N. E. D. Andrades, N. Paulino, et al., “Synthesis and characterization of a metal complex containing naringin and Cu, and its antioxidant, antimicrobial, anti-inflammatory and tumor cell cytotoxicity,” Molecules, vol. 12, no. 7, pp. 1352–1366, 2007.

[23] F. V. So, N. Guthrie, A. F. Chambers, M. Moussa, and K. K. Carroll, “Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices,” Nutrition and Cancer, vol. 26, no. 2, pp. 167–181, 1996.

[24] L.-C. Chiang, L. T. Ng, I.-C. Lin, P.-L. Kuo, and C.-C. Lin, “Anti-proliferative effect of apigenin and its apoptotic induction in human HepG2 cells,” Cancer Letters, vol. 237, no. 2, pp. 207–214, 2006.

[25] B.-D. Wang, Z.-Y. Yang, Q. Wang, T.-K. Cai, and P. Crewdon, “Synthesis, characterization, cytotoxic activities, and DNA-binding properties of the La(III) complex with naringenin Schiff-base,” Bioorganic & Medicinal Chemistry, vol. 14, no. 6, pp. 1880–1888, 2006.

[26] T.-R. Li, Z.-Y. Yang, B.-D. Wang, and D.-D. Qin, “Synthesis, characterization, antioxidant activity and DNA-binding studies of two rare earth(III) complexes with naringenin-2-hydroxy benzoyl hydrazone ligand,” European Journal of Medicinal Chemistry, vol. 43, no. 8, pp. 1688–1695, 2008.

[27] T.-R. Li, Z.-Y. Yang, and B.-D. Wang, “Synthesis, characterization and antioxidant activity of naringenin Schiff base and its Cu(II), Ni(II), Zn(II) complexes,” Chemical and Pharmaceutical Bulletin, vol. 55, no. 1, pp. 26–28, 2007.

[28] G. M. Escandar and L. F. Sala, “Complexing behavior of rutin and quercetin,” Canadian Journal of Chemistry, vol. 69, no. 1212, pp. 1994–2001, 1991.

[29] P. Viswanathan, V. Srijam, and G. Yogeewaran, “Sensitive spectrophotometric assay for 3-hydroxy-substituted flavonoids, based on their binding with molybdenum, antimony, or bismuth,” Journal of Agricultural and Food Chemistry, vol. 48, no. 7, pp. 2802–2806, 2000.

[30] E. Woźniacka, M. Kopacz, M. Umbreit, and J. Klos, “New complexes of La(III), Ce(III), Pr(III), Nd(III), Sm(III), Eu(III) and Gd(III) ions with morin,” Journal of Inorganic Biochemistry, vol. 101, no. 3, pp. 774–782, 2007.

[31] R. F. de Souza and W. F. de Giovani, “Synthesis, spectral and electrochemical properties of Al(III) and Zn(II) complexes with flavonoids,” Spectrochimica Acta Part A, vol. 61, no. 19, pp. 1985–1990, 2005.

[32] S. Yaman, P. de Hoog, G. Amadei, and J. Reedijk, “Platinated copper(3-clip-phen) complexes as effective DNA-cleaving and cytotoxic agents,” Chemistry, vol. 14, no. 11, pp. 3418–3426, 2008.

[33] Z.-F. Chen, Y.-C. Liu, L.-M. Liu, et al., “Potential new inorganic antitumour agents from combining the anticancer traditional Chinese medicine (TCM) lirioidenine with metal ions, and DNA binding studies,” Dalton Transactions, no. 2, pp. 262–272, 2009.

[34] D. R. Philip and V. R. Mikhail, “Thermodynamics of hydrogen bond and hydrophobic interactions in cyclodextrin complexes,” Biophysical Journal, vol. 71, no. 4, pp. 2144–2154, 1996.

[35] G.Gattuso, D.Barrera, C. Gargiulli, U. Leuzzi, and C. Caristi, “Flavonoid composition of citrus juices,” Molecules, vol. 12, no. 8, pp. 1641–1673, 2007.

[36] A. C. John and H. G. Petering, “The antitumor activity of Cu(II)KTS, the copper (II) chelate of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazone),” Cancer Research, vol. 27, no. 7, pp. 1278–1285, 1967.

[37] I. P. Gabriel, C. G. Anna, A. C. Hotze, C. Sanchez-Cano, B. M. Kariuki, and M. J. Hannon, “Dinuclear ruthenium(II) triple-stranded helicates: luminescent supramolecular cylinders that bind and coil DNA and exhibit activity against cancer cell lines,” Angewandte Chemie International Edition, vol. 46, no. 23, pp. 4374–4378, 2007.

[38] M. A. Galindo, D. Olea, M. A. Romero, et al., “Design and non-covalent DNA binding of platinum (II) metalacalixarenes,” Chemistry, vol. 13, no. 18, pp. 5075–5081, 2007.

[39] R. Tamilarasan and D. R. McMillin, “Photophysical studies of copper phenanthonoles bound to DNA,” Inorganic Chemistry, vol. 29, no. 15, pp. 2798–2802, 1990.

[40] A. Mazumder and D. M. Perrin, “Chemical nucleases,” Chemical Reviews, vol. 93, no. 6, pp. 2295–2316, 1993.
[41] K. A. Meadows, F. Liu, J. Sou, B. P. Hudson, and D. R. McMillin, “Spectroscopic and photophysical studies of the binding interactions between copper phenanthroline complexes and RNA,” *Inorganic Chemistry*, vol. 32, no. 13, pp. 2919–2923, 1993.

[42] H. Ihmel, B. Engels, K. Faulhaber, and C. Lennartz, “New dyes based on amino-substituted acridizinium salts-synthesis and exceptional photochemical properties,” *Chemistry*, vol. 6, no. 1S, pp. 2854–2864, 2000.

[43] C. M. Che, M. S. Yang, K. H. Wong, H. L. Chan, and W. Lam, “Platinum(II) complexes of dipyridophenazine as metallointercalators for DNA and potent cytotoxic agents against carcinoma cell lines,” *Chemistry: A European Journal*, vol. 5, no. 11, pp. 3350–3356, 1999.

[44] S. Mahadevan and M. Palaniandavar, “Spectroscopic and voltammetric studies on copper complexes of 2,9-dimethyl-1,10-phenanthrolines bound to calf thymus DNA,” *Inorganic Chemistry*, vol. 37, no. 4, pp. 693–700, 1998.

[45] S. Schäfer, I. Ott, R. Gust, and W. S. Sheldrick, “Influence of the polypyridyl (pp) ligand size on the DNA binding properties, cytotoxicity and cellular uptake of organoruthenium(II) complexes of the type [(η⁶-C₆Me₆)Ru(L)(pp)]⁺⁺ [L = Cl, n = 1; L = (NH₂)₂CS, n = 2],” *European Journal of Inorganic Chemistry*, vol. 2007, no. 19, pp. 3034–3046, 2007.

[46] H. Xu, K. C. Zheng, Y. Chen, et al., “Effects of ligand planarity on the interaction of polypyridyl Ru(II) complexes with DNA,” *Dalton Transactions*, no. 11, pp. 2260–2268, 2003.